The role of inflammation and anti-inflammatory therapy in irritable bowel syndrome (review and results of own research)
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 1
Abstract
The paper presents relevant data on the pathogenetic role of intestinal mucous inflammation at irritable bowel syndrome (IBS). It has been shown that with some IBS subtypes, especially post-infectious IBS, the inflammation may be of key significance in the developing of low-intensity inflammatory reaction and symptoms emergence. Mast cells, intestinal barrier dysfunction, intestinal pathogens and genetic predisposition are of great importance in the development of such inflammation. In IBS patients the inflammation may be a part of disease pathogenesis, which requires further study. Thus, IBS pathogenetic treatment may include anti-inflammatory agents, such as Mesalazine, Ketotifen and Sodium Cromoglycate, steroids, Omalizumab. The results of own investigation demonstrated that Montelukast in combination with Quifenadine as an adjunctive of the standard baseline therapy increased the treatment efficacy in IBS patients with concomitant allergic diseases, especially IBS-D subtype. In particular, both allergic and gastroenterological manifestations were reduced, pain intensity and diarrhea syndrome significantly attenuated, the overall health, vitality and physical condition of patients improved. These changes took place owing to following effects of combined therapy: blocking of the inflammatory mediators in mast cells, anti-spasmodic and desensitizing effects with additional relief of the constrictive and spasmogenic histamine effects on smooth muscles of the intestine. Moreover, Quifenadine has a moderate anti-serotonin effect which, plays an important role in IBS, taking into account its pathophysiological mechanisms. Thus, the combination of anti-leukotriene and antihistamines, along with the baseline therapy in patients with IBS and associated allergic diseases, provides a positive clinical and laboratory outcome, but requires further study.
Authors and Affiliations
A. R. Levchenko
Keywords
Related Articles
- EP ID EP508587
- DOI 10.30978/MG-2019-1-113
- Views 125
- Downloads 0
Selection of hepatoprotector in multimorbid diseases of hepatobiliary system
Objective — to study of the efficacy and tolerability of Artigel complex in the treatment of patients suffering from non-alcoholic fatty liver disease (NAFLD) in combination with chronic acalculous cholecystitis (CAC) wi...
Influence of non-alcoholic fatty liver disease on the cardiac hemodynamics indices and vascular disorders in patients with essential hypertension
Objective — to compare the structural and functional state of the heart, vessels and liver in patients with isolated EH and in conditions of its combination with NAFLD. Materials and methods. A total of 117 patients wit...
Pathogenetic role of visceral adipose tissue in the development of non-alcoholic fatty liver disease in patients with metabolic syndrome
Objective — to study the nature of changes in carbohydrate and lipid metabolism, depending on the distribution and activity of visceral adipose tissue (VAT), and the degree of liver steatosis in patients with nonalcoholi...
Functional dyspepsia and immune dysfunction: modern concepts of pathogenetic mechanisms of their development
The review presents the main modern opinions on the immunological factors of functional dyspepsia development and data on its micromorphological basis. The immune dysfunction is considered as an important factor in the p...
The ways of antihelicobacter therapy in Ukraine (based on the data of analysis of the Ukrainian Registry Hp-EuReg — UKRAINE)
Objective — to assess the state of affairs in the diagnosis and treatment of Helicobacter pylori infection in Ukraine and their conformity with the modern international recommendations. Materials and methods. The perfor...